[RESEARCH BLOG] · 2026-07-22
Hims & Hers Health, Inc. (HIMS) – Sell‑Flip Signal Amid Crisis‑Mode Market Regime
By Pierre Brunelle · Founder & Research Lead
Lede: Hims & Hers closed at $32.73, up 0.09 % as of 2026‑07‑21 (Tuesday), as LOPJLB’s proprietary model flipped the directional bias to SELL and flagged a CRISIS market regime, assigning the stock a ‑5 composite score.
Recent News Flow
-
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company – Business Wire, 2026‑07‑17 16:17 UTC. The filing notes that Becklund’s exit will be effective later this quarter and that the board will begin a search for a successor with experience scaling digital‑health finance operations.
-
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know – Zacks, 2026‑07‑14 18:45 UTC. The piece highlights that, despite a modest share‑price rise, HIMS delivered revenue growth that outstripped the S&P 500’s 5 % annual gain, driven by expanding subscription‑based telehealth services and a broadened product portfolio that now includes over‑the‑counter wellness items.
-
Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026 – Business Wire, 2026‑07‑13 16:05 UTC. The notice previewed a Q2 release on 2026‑08‑10, indicating management expects continued double‑digit top‑line growth but warned of lingering cost‑structure pressures as the firm invests in new clinical platforms.
-
Is Most‑Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? – Zacks, 2026‑07‑13 10:01 UTC. The analysis examined the stock’s volatile price action and high forward valuation multiples, pointing to a widening gap between analyst price targets ($29.67) and the current market price.
-
Hims & Hers Health: The Market Still Doesn't Get It – Seeking Alpha, 2026‑07‑08 08:34 UTC. The author argues that the market undervalues the company’s subscription churn rate and cross‑sell potential, contending that HIMS’s digital platform creates a defensible moat despite negative earnings and elevated leverage.
Fundamentals and Valuation
Hims & Hers operates a fully digital health platform that connects consumers with licensed clinicians for prescription and wellness services. The company’s financial profile reflects rapid growth tempered by profitability challenges and a capital‑intensive balance sheet.
Valuation snapshot (as of the latest filing):
| Metric | Value |
|---|---|
| Forward P/E (FY) | 79.46 |
| EV/EBITDA | 273.2 |
| Gross margin | 67.64 % |
| Operating margin | 1.32 % |
| Net margin | –0.56 % |
| ROIC | 1.82 % |
| Debt‑to‑Equity (D/E) | 253.7 % |
| Analyst target price | $29.67 (Hold) |
The trailing P/E of ‑654.6 underscores that the firm remains loss‑making on a GAAP basis, a condition that has persisted since 2020 when HIMS posted a negative EPS of ‑$0.51 on revenue of $148.8 M. By the end of 2025, EPS turned positive at $0.57 on revenue of $2.35 B, delivering a forward‑looking P/E of 56.9 for that year. The current forward multiple of 79.46 signals that the market still expects earnings to accelerate sharply, a premise that hinges on the firm’s ability to convert its high gross margin (averaging ~78 % over the past six years) into sustainable operating profit.
Revenue growth has been the standout metric, expanding from $148.8 M in 2020 to $2.35 B in 2025—a 13‑fold increase, or an average annual growth rate of roughly 84 %. The most recent annual growth figure listed in the fundamentals sheet is 32.81 %, indicating a slowdown from the double‑digit expansion of earlier years but still outpacing the broader healthcare sector, which grew at roughly 9 % in 2025.
Margins tell a more nuanced story. Gross margins have remained robust, hovering between 73 % and 82 %, reflecting the low‑cost nature of digital prescription fulfillment. Operating margins, however, have been volatile: a deep‑negative ‑42 % in 2021 gave way to a modest 4.5 % in 2025. Net margins turned positive only in 2024 (8.54 %) and 2025 (5.47 %), suggesting that cost‑control initiatives—particularly in technology and marketing spend—are beginning to bear fruit.
Free‑cash‑flow (FCF) generation has also shifted. After a series of negative FCF years (e.g., ‑$6.7 M in 2020 and ‑$39.4 M in 2021), the firm posted a positive $46.99 M in 2023 and $73.96 M in 2025. The FCF yield of 1.04 % is modest but signals that cash conversion is improving. The buyback yield of 1.23 % indicates that management is returning a small portion of cash to shareholders, though the scale is limited relative to the company’s market cap of $7.30 B.
Leverage remains a concern. The Debt‑to‑Equity ratio of 253.7 % is markedly higher than the industry average of roughly 80 %, and the interest coverage figure of 999.0 appears anomalously high, likely reflecting the low absolute interest expense rather than a true cushion. Nonetheless, the high leverage amplifies the risk profile, especially if revenue growth stalls.
The Altman Z‑score of 3.60 places HIMS just above the conventional bankruptcy threshold of 1.8, suggesting that while the firm is not in immediate distress, its financial structure is fragile. The PEG ratio of 1.80 implies that the stock’s forward earnings growth expectations are priced at nearly twice the growth rate, a level that typically warrants caution for growth‑oriented investors.
Analyst sentiment is neutral, with a consensus Hold rating and a target price of $29.67, which is ~9 % below the current market price. This discrepancy reflects a modest discount that analysts apply to the company’s forward earnings outlook, perhaps accounting for the elevated debt load and the uncertainty surrounding sustained profitability.
Multi‑Year Performance Overview
| Year | Revenue ($M) | EPS ($) | Gross Margin | Op. Margin | Net Margin | ROE (%) | ROA (%) |
|---|---|---|---|---|---|---|---|
| 2020 | 148.8 | ‑0.51 | 73.58 % | ‑10.18 % | ‑12.18 % | 12.33 | ‑15.26 |
| 2021 | 271.9 | ‑0.58 | 75.22 % | ‑42.31 % | ‑39.60 % | ‑32.17 | ‑25.60 |
| 2022 | 526.9 | ‑0.32 | 77.57 % | ‑13.04 % | ‑12.46 % | ‑21.07 | ‑17.93 |
| 2023 | 872.0 | ‑0.11 | 81.99 % | ‑3.38 % | ‑2.70 % | ‑6.84 | ‑5.34 |
| 2024 | 1,476.5 | 0.58 | 79.45 % | 4.19 % | 8.54 % | 26.44 | 17.81 |
| 2025 | 2,347.6 | 0.57 | 73.84 % | 4.50 % | 5.47 % | 23.73 | 5.96 |
The table illustrates a classic “growth‑to‑profit” trajectory: early years marked by aggressive top‑line expansion and deep losses, followed by a turning point in 2024 when the company posted its first positive net margin and a double‑digit ROE. The upward swing in ROE from ‑6.84 % in 2023 to 26.44 % in 2024 underscores the impact of scaling the platform while keeping cost of goods sold low. However, the subsequent dip in net margin to 5.47 % in 2025 hints that the firm may be encountering diminishing returns on its growth spend, a factor that aligns with the current SELL signal.
ETF Ownership
Hims & Hers is held by a concentrated set of thematic and healthcare‑focused exchange‑traded funds. The top twelve holders collectively own roughly 38 % of the float, with the five largest positions listed below.
The prominence of these ETFs reflects investor interest in the “digital health” and “online retail” themes that have surged during the post‑pandemic era. Concentrated ETF ownership can amplify price movements when fund managers rebalance, especially in a CRISIS market regime where risk‑off flows may trigger simultaneous redemptions across multiple thematic vehicles. Consequently, HIMS’s price dynamics may be more sensitive to fund‑level sentiment than to pure fundamentals in the short term.
LOPJLB Signal Read
The LOPJLB proprietary engine has turned SELL on Hims & Hers, assigning a ‑5 composite score. The signal emerges from a CRISIS market regime, a three‑day classification that flags heightened systemic risk and elevated volatility.
- PERF (composite) score: 22.80
- FUND (quality) score: 40.80
- Growth score: 60.00
- GARP score: 48.00
- Archetype: Growth Compounder
While the stock exhibits strong growth characteristics, its quality metrics—particularly profitability and leverage—are lagging. In a crisis‑mode environment, growth‑compounders often experience sharper pullbacks because investors prioritize capital preservation over upside potential.
Readers are encouraged to explore the interactive chart on the HIMS stock page for a visual overlay of the signal, price action, and technical context. For a deeper dive into the methodology that drives these scores, see LOPJLB’s methodology page.
Further Research
- Detailed stock profile: https://www.lopjlb.com/stock/HIMS
- Earnings‑call archive (if applicable): https://www.lopjlb.com/stock/HIMS/earnings.md
- Full‑screen screener for comparable healthcare names: https://www.lopjlb.com/screener
The information provided herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.